CAPTRUST Financial Advisors
ABOS icon

CAPTRUST Financial Advisors’s Acumen Pharmaceuticals ABOS Stock Holding History

CAPTRUST Financial Advisors’s Portfolio ABOS Stock Details ABOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-15,757
Closed -$37.2K – 3277
2026
Q1 		$37.2K Buy
+15,757
New +$40.2K ﹤0.01% 2924
2022
Q3 		– Sell
-1,000
Closed -$5K – 2069
2022
Q2 		$5K Sell
1,000
-576
-37% -$2.16K ﹤0.01% 4053
2022
Q1 		$6K Buy
+1,576
New +$8.57K ﹤0.01% 4044
2021
Q4 		– Sell
-78
Closed -$1K – 4748
2021
Q3 		$1K Buy
+78
New +$1.3K ﹤0.01% 4391

Other funds holding ABOS

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $614M AUM 19.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
KIA
Knollwood Investment Advisory Hunt Valley, Maryland $1.12B AUM 41.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

CAPTRUST Financial Advisors's ABOS Position: Q2 2026 in Review

CAPTRUST Financial Advisors sold out of Acumen Pharmaceuticals (ABOS) in Q2 2026, closing a stake of 15,757 shares — an estimated $37.2K sold.

CAPTRUST Financial Advisors first reported a position in ABOS in Q3 2021 and held it in 4 quarters. The position peaked at $37.2K in Q1 2026. 96 funds tracked by Wall St. Rank hold ABOS as of Q2 2026.

  • CAPTRUST Financial Advisors reported no remaining Acumen Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • CAPTRUST Financial Advisors sold 15,757 Acumen Pharmaceuticals shares in Q2 2026, an estimated $37.2K.
  • CAPTRUST Financial Advisors first reported a position in Acumen Pharmaceuticals in Q3 2021 and held it in 4 quarters.
  • CAPTRUST Financial Advisors's Acumen Pharmaceuticals position peaked at $37.2K in Q1 2026.
  • 96 funds tracked by Wall St. Rank held Acumen Pharmaceuticals as of Q2 2026.

Based on CAPTRUST Financial Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.